- Home
- MORF
MORF
Morphic Holding Inc.
as 07-26-2024 4:00pm EST
Morphic Holding Inc is a biopharmaceutical company applying its insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.
Upcoming Earnings Alert:
Get ready for potential market movements as Morphic Holding Inc. MORF prepares to release earnings report on 01 Aug 2024.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 2.8B | IPO Year: | 2019 |
| Target Price: | $56.60 | AVG Volume (30 days): | 5.5M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $19.35 - $62.08 | Next Earning Date: | 08-01-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -44.06% | Revenue Growth (next year): | 16.67% |
Stock Insider Trading Activity of Morphic Holding Inc. (MORF)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| DeVaul William | MORF | General Counsel and Secretary | Jul 8 '24 | Sell | $55.79 | 10,000 | $557,907.00 | 23,029 | SEC Form 4 |
| Farrell Robert E Jr | MORF | SVP Finance and CAO | Jul 8 '24 | Sell | $55.80 | 30,272 | $1,689,177.60 | 13,781 | SEC Form 4 |
| SCHEGERIN MARC | MORF | CFO and COO | Jul 8 '24 | Sell | $55.80 | 43,936 | $2,451,628.80 | 37,907 | SEC Form 4 |
| SCHEGERIN MARC | MORF | CFO and COO | Jan 12 '24 | Sell | $27.49 | 6,041 | $166,071.32 | 37,460 | SEC Form 4 |
| Rogers Bruce | MORF | President | Jan 12 '24 | Sell | $27.49 | 6,314 | $173,576.28 | 142,036 | SEC Form 4 |
| DeVaul William | MORF | General Counsel and Secretary | Jan 12 '24 | Sell | $27.49 | 4,509 | $123,955.57 | 23,029 | SEC Form 4 |
| Farrell Robert E Jr | MORF | SVP Finance and CAO | Jan 12 '24 | Sell | $27.49 | 5,089 | $139,900.17 | 34,992 | SEC Form 4 |
| Tipirneni Praveen P. | MORF | CEO | Jan 12 '24 | Sell | $27.49 | 13,923 | $382,753.02 | 42,013 | SEC Form 4 |
| Edwards Martin | MORF | Director | Nov 13 '23 | Buy | $20.54 | 2,376 | $48,803.04 | 2,376 | SEC Form 4 |
| SLATTERY JOSEPH P | MORF | Director | Nov 13 '23 | Buy | $20.60 | 2,400 | $49,435.68 | 9,066 | SEC Form 4 |
Latest Morphic Holding Inc. News
MORF Breaking Stock News: Dive into MORF Ticker-Specific Updates for Smart Investing
BioPharma Dive
8 days ago
Lilly alone in bidding for Morphic; Novartis won’t yet file MorphoSys drug
MT Newswires
12 days ago
Jefferies Downgrades Morphic Holding to Hold From Buy, Price Target is $57
Zacks
14 days ago
Pharma Stock Roundup: LLY to Buy Morphic, PFE Advances Obesity Drug Development
MT Newswires
16 days ago
Morphic Holding Insider Sold Shares Worth $1,689,178, According to a Recent SEC Filing
MT Newswires
16 days ago
Morphic Holding Insider Sold Shares Worth $1,204,075, According to a Recent SEC Filing
Zacks
17 days ago
Eli Lilly (LLY) to Buy Morphic for $3.2B, Boost IBD Presence
Zacks
17 days ago
Company News for July 9, 2024
MT Newswires
18 days ago
BMO Capital Downgrades Morphic Holding to Market Perform From Outperform, Raises Price Target to $57 From $52
Compare MORF vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MORF Morphic Holding Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.